Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 2.3% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 19.2% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: adjuvanttherapyuncontrolledsurgerygrowth
  Phrases that lowered it: clinically significantangiotensinlosartanclinicalcriteria
• Drug's FAERS reports before start: 89401 (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Minimum age: not given (raises risk) · Who can join
• Sponsor's past trials: 87 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 82.5% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Blinding: double (raises risk) · Design
• Responsible party: sponsor (raises risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Short-term Additive Effect of Topical Ketorolac on the Management of Diabetic Macular Edema With Intravitreal Bevacizumab NCT04119921 · started 2018 · scored riskier than 4% of active trials completed
• Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema NCT01823081 · started 2013 · scored riskier than 8% of active trials completed
• Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema NCT01363440 · started 2011 · scored riskier than 43% of active trials completed
• Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema NCT00874744 · started 2008 · scored riskier than 9% of active trials completed
• Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement NCT01783886 · started 2013 · scored riskier than 22% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.